Swedish team: Omega-3 fatty acids cross blood-brain barrier for possible Alzheimer's treatment

Researchers at the Karolinska Institutet in Sweden have shown that omega-3 fatty acids can cross the blood-brain barrier in a potential treatment for Alzheimer's disease. Previous research has shown lower concentrations of the fatty acid in Alzheimer's patients' brains, and replacing them could lead to an effective treatment, the scientists think. But until this study, published in the Journal of Internal Medicine, delivering the supplement to the brain past the blood-brain barrier was undocumented. "In animals, DHA dietary supplements can lead to an increase in DHA concentrations in the CNS," said lead researcher Jan Palmblad in a statement. "Here we show that the same applies to humans, which suggests that omega-3 fatty acids in dietary supplements cross the blood-brain barrier. However, much work remains to be done before we know how these fatty acids can be used in the treatment of Alzheimer's disease to halt memory loss." More | Abstract

Suggested Articles

Kala Pharma's Eysuvis on Tuesday became the first and only corticosteroid approved to treat short-term signs and symptoms of dry eye disease.

Xeris scored an FDA fast track designation for its diazepam formulation, delivered via autoinjector, to treat acute repetitive seizures.

Armed with microrobots and magnetic fields, Pursue scientists are looking to the future of targeted drug delivery, starting with the colon.